{"product_id":"biolegend-317330","title":"Biolegend, 317330, Brilliant Violet 785™ anti-human CD3 Antibody, 100tests","description":"\u003cp\u003eCD3ε is a 20 kD chain of the CD3\/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α\/β or γ\/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.\u003cbr\u003e\n100tests\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.\u003cbr\u003e\nConcentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780\/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego. Li B, et al. 2005. Immunology 116:487. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed Alter G, et al. 2008. J. Virol. 82:9668. PubMed Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed Pinto JP, et al. 2010. Immunology. 130:217. PubMed Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed\u003cbr\u003e\nProduct Citations: Ivarsson M, et al. 2016. Mucosal Immunol. 10.1038\/mi.2016.50. PubMed Robinson GA, et al. 2021. EBioMedicine. 103243:. PubMed Vamva E, et al. 2023. Mol Ther Methods Clin Dev. 28:366. PubMed Tatari N, et al. 2022. Front Immunol. 13:905768. PubMed Woan KV, et al. 2021. Cell Stem Cell. 28:2062. PubMed Wu X, et al. 2022. Front Immunol. 13:811551. PubMed McEvoy CM, et al. 2022. Nat Commun. 13:7634. PubMed Arce Vargas F et al. 2018. Cancer cell. 33(4):649-663 . PubMed Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed Novakova L et al. 2018. Journal of neurochemistry. 146(3):322-332 . PubMed Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed Karim F, et al. 2021. Elife. 10:. PubMed Myers JA, et al. 2022. JCI Insight. :. PubMed Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed Asowata OE, et al. 2021. JCI Insight. 6:. PubMed Björklund \u0026amp;, et al. 2016. Nat Immunol. 17:451-460. PubMed Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed Wang N, et al. 2021. iScience. 24:103205. PubMed Lisovsky I, et al. 2015. J Virol. 89: 9909 - 9919. PubMed Fisher J, et al. 2017. Mol Ther. 10.1016\/j.ymthe.2017.03.002. PubMed Jackson E, et al. 2017. PLoS One. 10.1371\/journal.pone.0185160. PubMed Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed Jin Y et al. 2019. Nature communications. 10(1):391 . PubMed Neff CP et al. 2018. EBioMedicine. 30:192-202 . PubMed Davis JE, et al. 2021. J Transl Med. 19:473. PubMed Nel I, et al. 2021. Diabetologia. 64(10):2306-2321. PubMed Wu X, et al. 2018. J Immunol Methods. 455:71. PubMed Moore T,et al. 2017. Cancer Immunol Immunother. . 10.1007\/s00262-017-2073-0. PubMed Huber JE, et al. 2020. J Immunol. 204:1101. PubMed Li N, et al. 2021. Cell Rep Med. 2:100297. PubMed Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed Isitman G, et al. 2016. PLoS One. 11:e0164517. PubMed Thieme CJ, et al. 2020. Cell Rep Med. 1:100092. PubMed Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed Singh A, et al. 2020. Cell Rep. 32:108153. PubMed Bradley D, et al. 2022. Nat Commun. 13:5606. PubMed Menges D, et al. 2022. Nat Commun. 13:4855. PubMed Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed Wu X, et al. 2020. Front Immunol. 1.922222222. PubMed Martinez EM, et al. 2018. SLAS Discov. 1.377083333. PubMed Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed Bruno L, et al. 2016. Immunol Cell Biol. 10.1038\/icb.2016.49. PubMed Ferreira-Gomes M, et al. 2021. Nat Commun. 12:1961. PubMed Dersh D, et al. 2020. Immunity. 54(1):116-131.e10. PubMed Ogongo P, et al. 2020. J Clin Invest. 130:214. PubMed\u003cbr\u003e\nRRID: AB_11219196 (BioLegend Cat. No. 317329) AB_2563507 (BioLegend Cat. No. 317330)\u003cbr\u003e\nStructure: Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α\/β or γ\/δ) form the CD3\/TCR complex, 20 kD\u003cbr\u003e\nDistribution: Mature T and NK T cells, thymocyte differentiation\u003cbr\u003e\nFunction: Antigen recognition, signal transduction, T cell activation\u003cbr\u003e\nLigand\/Receptor: Peptide antigen bound to MHC\u003cbr\u003e\nCell Type: NKT cells, T cells, Thymocytes, Tregs\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: CD Molecules\u003cbr\u003e\nAntigen References: Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego. Beverly P, et al. 1981. Eur. J. Immunol. 11:329. Lanier L, et al. 1986. J. Immunol. 137:2501.\u003cbr\u003e\nGene ID: 916\u003cbr\u003e\nUniProt: View information about CD3 on UniProt.org\u003cbr\u003e\nClone: OKT3\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nWorkshop: HCDM listed\u003cbr\u003e\nOther Names: T3, CD3ε\u003cbr\u003e\nIsotype: Mouse IgG2a, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46866158977193,"sku":"317330","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-317330","provider":"Iright","version":"1.0","type":"link"}